SCHEMBL4540037

SCHEMBL4540037

CCNc1cccc(COc2c(Br)cc(C(=O)NCC(=O)O)cc2Br)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRA P10827 8/20 0.69
THRB P10828 8/20 0.69
SMN1; SMN2 Q16637 2/20 0.48
PDE5A O76074 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
ESR1 P03372 1/20 0.45
NR3C1 P04150 1/20 0.45
PGR P06401 1/20 0.45
NR3C2 P08235 1/20 0.45
AR P10275 1/20 0.45
LMNA P02545 2/20 0.43
HPGD P15428 1/20 0.43
NR1H4 Q96RI1 1/20 0.43
GLA P06280 1/20 0.42
SIRT2 Q8IXJ6 1/20 0.41
SIRT1 Q96EB6 1/20 0.41
SIRT3 Q9NTG7 1/20 0.41
SENP5 Q96HI0 1/20 0.41
SENP2 Q9HC62 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5718290 0.96 THRA (0.64) THRATHRBSMN1; SMN2PDE5AMEN1
SCHEMBL4356831 0.92 THRA (0.58) THRATHRBSMN1; SMN2PDE5AMEN1
SCHEMBL4347509 0.89 THRA (0.57) THRATHRBSMN1; SMN2PDE5AMEN1
SCHEMBL4354874 0.89 THRA (0.53) THRATHRBSMN1; SMN2PDE5AMEN1
SCHEMBL4351576 0.88 THRA (0.53) THRATHRBSMN1; SMN2PDE5AMEN1
SCHEMBL4349556 0.87 THRA (0.52) THRATHRBSMN1; SMN2PDE5AMEN1
SCHEMBL4361817 0.87 THRA (0.52) THRATHRBSMN1; SMN2PDE5AMEN1
SCHEMBL5718292 0.87 THRA (0.57) THRATHRBSMN1; SMN2MEN1KMT2A
SCHEMBL4348053 0.87 THRA (0.52) THRATHRBSMN1; SMN2PDE5AMEN1
SCHEMBL4354094 0.86 THRB (0.50) THRATHRBSMN1; SMN2PDE5AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009080835-A1 THYROMIMETRIC COMPOUNDS IN TREATMENT OF DISEASE RELATED TO SONIC HEDGEHOG SIGNALLING KARO BIO AB (SE) 2009-07-02 WO disclosed
US-20080221210-A1 Thyroid Receptor Agonists KARO BIO AB (SE) 2008-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221210-A1 Thyroid Receptor Agonists TSHR, TRHR, THRA THRA 3/4885THRB 4/4885SMN1; SMN2 4282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.